Clinical utility of plasma p‐tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease
Open Access
- 14 January 2025
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (2) , e14502
Abstract
INTRODUCTION: Using an Asian cohort with high prevalence of concomitant cerebrovascular disease (CeVD), we evaluated the performance of a plasma immunoassay for tau phosphorylated at threonine 217 (p‐tau217) in detecting amyloid beta positivity (Aβ+) on positron emission tomography and cognitive decline, based on a three‐range reference, which stratified patients into low‐, intermediate‐, and high‐risk groups for Aβ+. METHODS: Brain amyloid status (Aβ– [ n = 142] vs Aβ+ [ n = 73]) on amyloid PET scans was assessed along with the plasma ALZpath p‐tau217 assay to derive three‐range reference points for PET Aβ+ based on 90% sensitivity (lower threshold) and 90% specificity (upper threshold). RESULTS: Plasma p‐tau217 (area under the curve [AUC] = 0.923) outperformed routine clinical assessments (AUC = 0.760–0.819; p ≤ 0.003) and other plasma biomarkers (AUC = 0.817–0.834; p < 0.001). The high‐risk group showed significantly higher rates of cognitive decline than the low‐risk group. DISCUSSION: Risk stratification for PET Aβ+ based on a plasma p‐tau217 assay demonstrated potential diagnostic and prognostic utility in an Asian cohort with concomitant CeVD. Highlights: The utility of plasma p‐tau217 to detect brain amyloid beta pathology (Aβ+) was studied in an Asian cohort with concomitant cerebrovascular disease Plasma tau phosphorylated at threonine 217 (p‐tau217) showed superior utility in detecting Aβ+ compared to neuroimaging measures, clinical workup, or other blood biomarkers including p‐tau181, glial fibrillary protein (GFAP), and Aβ Higher plasma p‐tau217 correlated with faster cognitive decline Plasma p‐tau217 shows promise as an Alzheimer's disease (AD) diagnostic and prognostic biomarker in diverse populationsKeywords
This publication has 30 references indexed in Scilit:
- Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary CareJAMA, 2024
- Head‐to‐head comparison of leading blood tests for Alzheimer's disease pathologyAlzheimer's & Dementia, 2024
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Association of plasma GFAP with elevated brain amyloid is dependent on severity of white matter lesions in an Asian cognitively impaired cohortAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2024
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease PathologyJAMA Neurology, 2024
- The potential clinical value of plasma biomarkers in Alzheimer's diseaseAlzheimer's & Dementia, 2023
- Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassaysAlzheimer's & Dementia, 2022
- Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease ContinuumJAMA Neurology, 2021
- Plasma P‐tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular diseaseAlzheimer's & Dementia, 2021
- Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) multicenter studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016